# Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)

> **NCT01884597** · PHASE1,PHASE2 · COMPLETED · sponsor: **Hawaii Pacific Health** · enrollment: 24 (actual)

## Conditions studied

- PCV
- Polypoidal Choroidal Vasculopathy

## Interventions

- **DRUG:** high-dose ranibizumab
- **DRUG:** ranibizumab

## Key facts

- **NCT ID:** NCT01884597
- **Lead sponsor:** Hawaii Pacific Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01884597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01884597, "Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01884597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*